AbbVie submits application for treatment in psoriasis

AbbVie has submitted a marketing authorisation application to the European Medicines Agency and a Biologics License Application to the US Food and Drug Administration for risankizumab, an investigational interleukin-23 inhibitor for the treatment of plaque psoriasis.

Michael Severino, executive vice president, research and development and chief scientific officer, AbbVie, said: “The risankizumab submission to the EMA marks another significant milestone in helping to advance treatment for people living with immune-mediated diseases. Many psoriasis patients are still battling this disease and the impact it has on their lives. Risankizumab has the potential to be an important new treatment option and we look forward to working with the EMA throughout the review process”.